Takeda's New Psoriasis Pill Outperforms Rival, Eyes Market Disruption

TORONTO, ON – June 23, 2026

The landscape of psoriasis treatment is on the verge of a significant shift. Takeda Pharmaceutical today announced compelling topline results from a pivotal Phase 3 study, revealing that its investigational once-daily pill, zasocitinib, demonstrated clear superiority over an existing oral therapy for moderate-to-severe plaque psoriasis. The head-to-head trial showed that zasocitinib not only met all its primary and secondary goals but achieved levels of complete skin clearance that could redefine expectations for patients and physicians alike.

The announcement sends a clear signal to a competitive multi-billion dollar market: a new, potentially best-in-class oral treatment is on the horizon. For the estimated 64 million people worldwide living with psoriasis, the results offer a new wave of optimism for a convenient therapy that doesn't compromise on efficacy. The drug, a next-generation tyrosine kinase 2 (TYK2) inhibitor, outperformed deucravacitinib, a first-in-class TYK2 inhibitor from Bristol Myers Squibb that set a new standard upon its own approval. This direct victory positions Takeda to make a major strategic play in the immunology space.

Redefining the Goal: The Promise of Complete Clearance

For decades, the goal of psoriasis treatment has been gradual improvement—managing symptoms and achieving partial skin clearance. However, Takeda's LATITUDE Atlas study challenges this paradigm. In the 16-week trial involving 606 participants, more than 35% of patients taking zasocitinib achieved a Psoriasis Area and Severity Index (PASI) 100 score, which signifies complete skin clearance. This result was more than 2.5 times the response rate seen in patients taking deucravacitinib.

This isn't just a statistical victory; it's a life-changing prospect for patients. Plaque psoriasis is a chronic, immune-mediated disease that manifests as painful, itchy, and disfiguring skin plaques. Its impact extends far beyond the physical, often leading to social isolation and significant mental health challenges. While powerful injectable biologics have offered high clearance rates for years, a significant portion of patients express a strong preference for oral medications, citing fear of needles and the convenience of a pill. Zasocitinib promises to bridge that gap, offering biologic-level efficacy in an oral form.

"For patients living with moderate-to-severe plaque psoriasis, achieving complete skin clearance remains an important treatment goal," said Linda Stein Gold, M.D., principal investigator for the study and Director of Dermatology Clinical Research at Henry Ford Health. "These head-to-head Phase 3 results are encouraging because they show the potential for an oral therapy to deliver high levels of skin clearance."

The study also demonstrated statistical superiority across all key secondary endpoints, including PASI 90 (near-complete clearance) and a Static Physician's Global Assessment (sPGA) score of 0 (clear). The safety profile remained consistent with previous studies, with no new safety signals identified, a crucial factor for any drug intended for long-term use in a chronic condition.

The Science of Superior Selectivity

The remarkable efficacy of zasocitinib lies in its molecular design. It is what Takeda calls a "next-generation, highly selective oral TYK2 inhibitor." TYK2 is an intracellular enzyme that plays a critical role in mediating inflammatory signals, particularly the IL-23 pathway, which is a core driver of psoriasis. By inhibiting TYK2, the drug effectively dials down the overactive immune response that causes skin cells to multiply too quickly.

While deucravacitinib was the first drug to successfully target TYK2 selectively, zasocitinib appears to have taken this approach a step further. According to Takeda, in-vitro data shows zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other enzymes in the Janus kinase (JAK) family (JAK1, 2, and 3). This ultra-high selectivity is key. Broader-acting JAK inhibitors, while effective, come with safety warnings due to their impact on other biological processes.

According to one clinical pharmacologist not involved in the study, "The goal with these next-generation molecules is to thread the needle—to maximize the inhibition of the disease-driving pathway while leaving other essential signaling pathways untouched. This level of selectivity could be the key to unlocking higher efficacy without introducing the safety liabilities of less targeted agents." This precision targeting may explain both the high clearance rates and the consistent safety profile observed in the trials.

A Calculated Move in a Crowded Market

Takeda's decision to run a head-to-head trial against an established market player was a bold and calculated risk. In the fiercely competitive psoriasis market—which surpassed $29 billion in 2025—simply proving a drug works is no longer enough. To capture significant market share, a new entrant must demonstrate clear differentiation. By proving superiority over deucravacitinib, Takeda has equipped itself with a powerful marketing tool and a compelling case for physicians and payers.

The oral psoriasis space is becoming increasingly crowded. It includes Amgen’s Otezla (apremilast), a PDE4 inhibitor with lower efficacy, and BMS’s Sotyktu (deucravacitinib), which generated $246 million in the past year. Furthermore, Johnson & Johnson is expected to launch its oral IL-23 receptor blocker, icotrokinra, which also promises biologic-like efficacy. Zasocitinib will enter this fray not as just another option, but as a potential new oral leader.

"These Phase 3 results reinforce the potential of zasocitinib as a meaningful oral treatment option," said Thiago Magalhães, Head of Specialty BU, Takeda Canada. Takeda has estimated that zasocitinib could achieve peak annual sales between $3 billion and $6 billion, an ambitious target that hinges on approvals not just in psoriasis but in other immune-mediated diseases as well.

The Path Forward to Patients

With these robust results in hand, Takeda is moving swiftly toward commercialization. The company confirmed it is on track to submit a New Drug Application for plaque psoriasis to the U.S. Food and Drug Administration (FDA) and other global regulatory bodies starting this fiscal year, which for Takeda began in April 2026. Detailed data from the LATITUDE Atlas study will be presented at upcoming medical congresses, where it will undoubtedly be a major topic of discussion among dermatologists.

Takeda’s ambition for zasocitinib extends well beyond psoriasis. The drug is currently in Phase 3 studies for psoriatic arthritis and Phase 2 studies for a range of other debilitating immune-mediated conditions, including Crohn's disease, ulcerative colitis, and vitiligo. This broad development program highlights Takeda's belief in the platform's potential and its strategy to build a multi-billion dollar franchise around this highly selective molecule. If successful, zasocitinib could become a foundational therapy across a wide spectrum of inflammatory diseases.